文献速递肝病

药理学抑制脂肪生成治疗非酒精性脂肪性肝病

Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.
PubMed 文献 · J Hepatol · 2023-11-15

非酒精性脂肪性肝病(NAFLD)中肝脏甘油三酯过度积聚是发病和进展的关键事件,而从头脂肪生成(DNL)速率增加是肝脂肪变性的核心。多种DNL相关酶已被药物抑制或寡核苷酸介导的敲低,先导化合物在II期临床试验中显示降低肝脂肪的疗效,人体中肝脂肪百分比下降与DNL抑制百分比密切平行,这些化合物的安全性特征迄今令人鼓舞,DNL抑制剂单用或联用有望成为NAFLD管理的重要药物。

要点

  • NAFLD中肝脏脂肪酸从头生成(DNL)速率增加是肝脂肪变性的核心环节。
  • 抑制DNL相关酶的先导化合物在II期临床试验中显示降低肝脂肪的疗效。
  • 人体中肝脂肪百分比下降与DNL抑制百分比密切平行,安全性特征迄今令人鼓舞。

核心结论

  • DNL抑制剂单用或与其他治疗药物联用,预期将成为人类NAFLD管理的重要药物。

研究设计与样本

  • 综述,总结药理学抑制脂肪生成治疗NAFLD的相关证据。

主要发现

  • NAFLD中肝脂肪变性源于血浆脂肪酸摄取与DNL增加,而脂肪酸氧化和极低密度脂蛋白-甘油三酯分泌不再与之平衡。
  • NAFLD中DNL增加主要由高胰岛素血症和高血糖驱动的转录机制所致,其效应器为一组特征明确的酶。
  • 多种DNL效应酶已被药物抑制或寡核苷酸介导的敲低,先导化合物在II期临床试验中显示降低肝脂肪的疗效。
  • 在NAFLD患者中,肝脂肪百分比下降与DNL抑制百分比密切平行。
  • 这些化合物的安全性特征迄今令人鼓舞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The hepatic accumulation of excess triglycerides is a seminal event in the initiation and progression of non-alcoholic fatty liver disease (NAFLD). Hepatic steatosis occurs when the hepatic accrual of fatty acids from the plasma and de novo lipogenesis (DNL) is no longer balanced by rates of fatty acid oxidation and secretion of very low-density lipoprotein-triglycerides. Accumulating data indicate that increased rates of DNL are central to the development of hepatic steatosis in NAFLD. Whereas the main drivers in NAFLD are transcriptional, owing to both hyperinsulinemia and hyperglycaemia, the effectors of DNL are a series of well-characterised enzymes. Several have proven amenable to pharmacologic inhibition or oligonucleotide-mediated knockdown, with lead compounds showing liver fat-lowering efficacy in phase II clinical trials. In humans with NAFLD, percent reductions in liver fat have closely mirrored percent inhibition of DNL, thereby affirming the critical contributions of DNL to NAFLD pathogenesis. The safety profiles of these compounds have so far been encouraging. It is anticipated that inhibitors of DNL, when administered alone or in combination with other therapeutic agents, will become important agents in the management of human NAFLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Esler WP, Cohen DE. Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. J Hepatol. 2023. PMID: 37977245. doi:10.1016/j.jhep.2023.10.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。